Personal data Dr. Marco Cosentino

marco_cosentinoMARCO COSENTINO
Born in Caltagirone (CT- Itàlia) el 19/12/1978
e-mail: androcosentino@gmail.com

Mobile: +393663483446

Contacta con el Dr. Marco Cosentino

 

 

 

 

Academic training

  • Degree in Medicine and Surgery (vote 107/110) from 30/10/2003, University of Catania;
  • Specialization in Urology (70/70 cum laude) 09/01/2009, Postgraduate School of Urology at the University of Padua, Director Prof. Walter Artibani.

Thesis specialties: Concordance between histological biopsy and final histology in patients with renal cancer

  • Fellow of the European Board of Urology F.E.B.U. from 06/06/2009;
  • PhD in Surgery, 08/07/2013, (European Doctor cum laude) Universitat Autonoma de Barcelona.

Thesis title: Radical Cystectomy and urinary diversion: is there a role for bowel in the future?

  • Specialization in Andrology, (01/06/2013 – 30/06/2015) Universitat Autonoma de Barcelona, Fundaciò Puigvert, Barcelona, Spain.
  • Master in Clinic Andrology and Sexual Medicine (2015-2017) Università degli Studi di Padova.

Professional and Clinical Experience

  • From June 2013 to June 2015 Fellowship Andrology Unit, Fundacio Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. Training in Clinical Andrology; Prosthesis Implantation; Peyronie disease medical and surgical treatment; Microsurgery in Andrology-Urology; Male Fertility Problems; Sexual Dysfunction; Sexual Transmitted Disease.;
  • From November 2012 to May 2013 Consultant Urologist of the Male/Female Incontinence and Urodynamic Unit at Fundació Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. Clinical and surgical activities in functional urology field, with specific focus on male and female incontinence and bladder disorders. Mentor of the residents in urology at 4th year of specialization, specifically for the endoscopic treatment of overactive bladder with Toxin Botulin (BoTox and Dysport);
  • From April 2012 to October 2012, Consultant Urologist of the Uro-Onclogy, Pediatric Urology and Endoscopic Department at Fundaciò Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. Open Surgery; Endoscopic Surgery; Clinical Research in the field of Uro-Oncology and Pediatric Urology;
  • From April 2011 to March 2012 Consultant Urologist of the Pediatric Urology Department at Fundaciò Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. Clinical and surgical activities in pediatric urology field with specific focus on medical, endoscopic, endo-urological and surgical treatment of enuresis, bladder disorders, vesico-ureteral reflux, urinary tract stones and many uro-pediatric pathologies;
  • From October 2010 to April 2011, Consultant Urologist of the Male/Female Incontinence and Urodynamic Unit at Fundació Puigvert – Universitat Autonoma de Barcelona, Barcelona, Spain. Clinical and surgical activities in functional urology field, with specific focus on male and female incontinence and bladder disorders. Mentor of the residents in urology at 4th year of specialization, specifically for the endoscopic treatment of overactive bladder with Toxin Botulin (BoTox and Dysport);
  • From October 2009 to September 2010 Fellow of the Uro-Onclogy Department at Fundaciò Puigvert, Universitat Autonoma de Barcelona, Barcelona, Spain. Laparoscopic and Open Surgery; Endoscopic Surgery; Clinical Research in the field of Uro-Oncology.

Publications Last 4 Years

  • Cosentino M, Peraza MF, Vives A, Sanchez J, Moreno D, Perona J, Ortiz G, Alcoba M, Ruiz E, Sarquella J. Factors predicting success after microsurgical vasovasostomy. Int Urol Nephrol. 2018, 50(4), 625-632.
  • Ledda A, Belcaro G, Dugall M, Luzzi R, Hosoi M, Feragalli B, Cotellese R, Cosentino V, Cosentino M, Eggenhoffner R, Pellizzato M, Fratter A, Giacomelli L. A natural pharma standard supplement formulation to control treatment-related toxicity and oxidative stress in genitourinary cancer: a preliminary study. Eur Rev Med Pharmacol Sci. 2017 Sep;21(18):4196-4202. PMID: 29028078
  • Cosentino M, Kanashiro A, Vives A, Sanchez J, Peraza MF, Moreno D, Perona J, De Marco V, Ruiz-Castañe E, Sarquella J. Surgical treatment of Peyronie’s disease with small intestinal submucosa graft patch. Int J Impot Res. 2016 Mar 31. doi: 10.1038/ijir.2016.10. [Epub ahead of print];
  • Cosentino V, Fratter A, Cosentino M. Anti-inflammatory effects exerted by Killox®, an innovative formulation of food supplement with curcumin, in urology. Eur Rev Med Pharmacol Sci. 2016 Apr;20(7):1390-8;
  • Vives Á, Vazquez A, Rajmil O, Cosentino M. Urethral condylomas in men: experience in 123 patients without previous treatment. Int J STD AIDS. 2015 Feb 22. pii: 0956462415574627. [Epub ahead of print];
  • Cosentino M, Sarquella J, Ruiz Castañe E. PRIAPISM SECONDARY TO TAMSULOSIN: A CASE REPORT. Revista International de Andrologia Jul 2014. DOI: 10.1016/j.androl.2014.07.007;
  • Cosentino M, Algaba F, Saldaña L, Bujons A, Caffaratti J, Garat JM, Villavicencio H. JUVENILE GRANULOSA CELL TUMOR OF THE TESTIS: A BILATERAL AND SYNCHRONOUS CASE. SHOULD TESTIS-SPARING SURGERY BE MANDATORY? Urology. 2014 Sep;84(3):694-6. doi: 10.1016/j.urology.2014.05.006. Epub 2014 Jul 19;
  • Cosentino M, Caffaratti J, Bujons A, Garat JM, Villavicencio H. TRATAMIENTO ENDOSCOPICO DEL REFLUJO VESICO-URETERAL. Published in “Focus” n.6, May 2014, 25-28;
  • Cosentino M, Caffaratti J, Bujons A, Garat JM, Villavicencio H. VESICO-URETERAL REFUX, ENDOSCOPIC MANAGEMENT. Arch Argent Pediatr. 2013 Aug;111(4):349-52. doi: 10.1590/S0325-00752013000400021;
  • Cosentino M.: “Alloplastic bladder substitution: are we making progress?”. UroToday.com Beyond the Abstract initiative. Published on Wednesday, January 9, 2013. Descargalo aquí;
  • Cosentino M, Breda A, Sanguedolce F, Landman J, Stolzenburg J-U, Verze P, Rassweiler J, Van Poppel H, Klingler HC, Janetschek G, Celia A, Kim FJ, Thalmann G, Nagele U, Mogorovich A, Bolenz C, Knoll T, Porpiglia F, Alvarez-Maestro M, Francesca F, Deho F, Eggener S, Abbou C, Meng MV, Aron M, Laguna P, Mladenov D, D’Addessi A, Bove P, Schiavina R, De Cobelli O, Merseburger AS, Dalpiaz O, D’Ancona FCH, Polascik TJ, Muschter R, Leppert TJ,Villavicencio H. THE USE OF MANNITOL IN PARTIAL AND LIVE DONOR NEPHRECTOMY: AN INTERNATIONAL SURVEY. World Journal of Urology 2012 Dic 15. WJUR2604R2. Volume 31, Issue 4 (2013), Page 977-982;
  • Cosentino M, Gaya J.M., Breda A, Palou J, Villavicencio H: ALLOPLASTIC BLADDER SUBSTITUTION: ARE WE MAKING PROGRESS? Int Urol Nephrol. Oct;44(5):1295-303. doi: 10.1007/s11255-012-0249-2. Epub 2012 Jul 21;
  • Gaya JM, Palou J, Cosentino M, Patiño D, Rodríguez-Faba O, Villavicencio H. A SECOND TRANSURETHRAL RESECTION COULD BE NOT NECESSARY IN ALL HUGH GRADE NON-MUSCLE-INVASIVE BLADDER TUMORS. Actas Urol Esp. Vol 36, Num 9, 2012 English, Spanish;
  • Cosentino M, Palou-Redorta J, Gaya-Sopena JM, Gich I, Breda A, Rodriguez-Faba O, Villavicencio-Mavrich H.: UPPER URINARY TRACT UROTHELIAL CELL CARCINOMA: LOCATION AS A PREDICTIVE FACTOR FOR CONCOMITANT BLADDER CARCINOMA. World J Urol. Epub 2012 May 3;
  • Cosentino M, A Breda, Sánchez-Martín FM, J Palou, J Caffaratti, H Villavicencio. “¿ES POSIBLE UNA VEJIGA ARTIFICIAL? PROGRESOS EN LAS ÚLTIMAS DÉCADAS”. Actas Fundació Puigvert Vol- 31, n.2-2012 pag 41-52;
  • J Caffaratti Sfulcini, JR Perez Carral, M Cosentino, A Bujons, JM Garat Barredo, H Villavicencio Mavrich. ACTUALIZACIÓN EN EL MANEJO DE LA LITIASIS PEDIÁTRICA. Rev Esp Pediatr 2012; 68(4): 295-301;

Scientific Research in International Projects

  • Single-Point contact of the International Cooperation Project under the 7th Framework Programme, Proposal entitled: “Integrated biomaterials and electronic components for a patient-controlled biofunctional artificial bladder”. Programme: Theme 4 – NMP – Nanosciences, Nanotechnologies, Materials and new Production Technologies. Call identifier: FP7-NMP-2011-SMALL-5 Stage 1. Proposal No: 280652-1 BioBladder CP-FP. Project do not passed stage 1 of the proposal;
  • Coordinator of the International Cooperation Project Under the 7th Framework Programme: “An urothelial mimicking patient-controlled bio-artificial neo-bladder integrating biologic, biomaterials and electronic components”. Call identifier: FP7-HEALTH-2012-INNOVATION-2; Proposal reference number: 304777-1; Call: FP7-HEALTH-2012-INNOVATION-2; Proposal acronym: Bio-Artificial Bladder. Project failed to pass stage 2 of the proposal.

Download the latest articless

  • Alloplastic bladder substitution: are we making progress?
  • Vesicoureteral reflux. endoscopic treatment
  • Improvement of seminal parameters and pregnancy rates after antegrade sclerotherapy of internal spermatic veins.
  • Is repercutaneous nephrolithotomy a safe and efective precedure for treatment of renal stones in children?
  • Juvenile Granulosa Cell Tumor of the Testis: A Bilateral and Synchronous Case. Should Testis-sparing Surgery Be Mandatory?
  • Laparoscopic Management of Spontaneous Retroperitoneal Hemorrhage
  • Actualización en el manejo de la Litiasi Pediatrica
  • The use of mannitol in partial and live donor nephrectomy: an international survey
  • Priapism secondary to tamsulosin: A case report
  • Prostate Biopsy: The Transperineal Approach
  • La re-resección transuretral puede no ser necesaria en todos los tumores vesicales no músculo-invasivos de alto grado
  • Can Tyrosine Kinase Inhibitors be Discontinued in Patients with Metastatic Renal Cell Carcinoma and a Complete Response to Treatment? A Multicentre, Retrospective Analysis
  • Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma
  • Urethral condylomas in men: experience in 123 patients without previous treatment